Back to User profile » Dr Steven Silverstein
Papers published by Dr Steven Silverstein:
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Retinal Microvasculature in Schizophrenia
Silverstein SM, Lai A, Green KM, Crosta C, Fradkin SI, Ramchandran RS
Eye and Brain 2021, 13:205-217
Published Date: 24 July 2021
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Visual Impairment and Mental Health: Unmet Needs and Treatment Options
Demmin DL, Silverstein SM
Clinical Ophthalmology 2020, 14:4229-4251
Published Date: 3 December 2020
Original Research
![Noteworthy comment: This paper is noteworthy because it describes a new tool to assess patients’ perspectives on a serious, often distressing aspect of a chronic mental illness—ie, cognitive impairment associated with schizophrenia. As recommended by the FDA’s guidance on patient-reported outcome (PRO) measures, the multistage development process utilized by the investigators incorporated quantitative and qualitative data from patients and providers. Given the importance to patients of receiving understandable information about their conditions, this new PRO measure may prove valuable in building a therapeutic alliance with patients with schizophrenia. Furthermore, following psychometric validation in an ongoing clinical trial, the measure could define key patient-oriented endpoints for future trials.](assets/img/article_icons/noteworthy.png)
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/rewwHVcpmts/1.jpg)
Welch LC, Trudeau JJ, Silverstein SM, Sand M, Henderson DC, Rosen RC
Patient Related Outcome Measures 2017, 8:71-81
Published Date: 8 June 2017